Drugs / Chlortalidone
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT04393493 | Jul 2017 → Apr 2020 | cardio-renal syndrome | Hospital Civil de Guadalajara | Completed | Missed primary |
| Phase 42 trials | ||||||
| Phase 4 | NCT02847338 | Nov 2016 → Oct 2023 | hypertensive disorder | Cambridge University Hospitals NHS Foundation Trust | Completed | No outcome recorded |
| Phase 4 | NCT02502981 | Jun 2014 → Feb 2018 | cardio-renal syndrome, chronic kidney disease | University Hospital Birmingham | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05976438 | Aug 2023 → Dec 2024 | hypertensive disorder | Cambridge University Hospitals NHS Foundation Trust | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT00408512 Comparator | Dec 2006 → Dec 2009 | essential hypertension | Federico II University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Chlortalidone | “GPs should use chlortalidone (12.5-25 mg daily) in the arm with compulsive thiazide diuretic as first line.” NCT00408512 ↗ |
| Known as | chlorthalidone | “General practitioners recruited 2,409 hypertensive patients with indication to antihypertensive therapy, who were randomized to start treatment with chlorthalidone (12.5-25 mg...” PMID 24956971 ↗ Jun 2014 |
| Route | Oral | “Drugs will be administered orally.” NCT00408512 ↗ |